Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

PURPOSE: Zoledronic acid (ZA) or denosumab treatment reduces skeletal-related events; however, the safety of prolonged therapy has not been adequately studied. Here, we describe safety results of extended denosumab therapy in patients with bone metastases from the open-label extension phase of two p...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Support Care Cancer
Autori principali: Stopeck, Alison T., Fizazi, Karim, Body, Jean-Jacques, Brown, Janet E., Carducci, Michael, Diel, Ingo, Fujiwara, Yasuhiro, Martín, Miguel, Paterson, Alexander, Tonkin, Katia, Shore, Neal, Sieber, Paul, Kueppers, Frank, Karsh, Lawrence, Yardley, Denise, Wang, Huei, Maniar, Tapan, Arellano, Jorge, Braun, Ada
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Berlin Heidelberg 2015
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4669370/
https://ncbi.nlm.nih.gov/pubmed/26335402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-015-2904-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi